© Reuters.
On Friday, Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) experienced a setback as Evercore ISI adjusted its rating on the company’s stock. Following the failure of Amylyx’s Phase 3 trial for its ALS treatment, the firm downgraded the stock from Outperform to In Line. The trial’s outcome was a disappointment to many who had high hopes for the potential treatment.
The Phase 3…
